Future studies using complementary mouse cohorts, ideally based on different liver cancer models, could be designed to explore the possibility of potentiating oncotherapy response, like those elicited by MEKi+BCL-XLi, blocking TIM3. This evidence concerns the gene HAVCR2 and liver cancer.